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CHAPTER 1 
INTRODUCTION 
1.1. MEDICINAL PLANTS 
India is the largest producer of medicinal plants and is rightly called the 
“Botanical garden of the World”. The medicinal plants, besides having natural 
therapeutic values against various diseases,also provide high quality of food and raw 
materials for livelihood. 
India has a rich culture of medicinal herbs and species, which include about 
more than 2000 species and has a vast geographical area with high potential abilities 
forAyurveda, Unani, Sidha traditional medicines but only very few have been 
studied chemically and pharmacologically for their potential medicinal value(Gupta 
et al., 2005;Sandhu and Heinrich, 2005). 
Human being have used plants for the treatment of diverse ailments for 
thousands of years. According to the World Health Organization, most populations 
stillrely on traditional medicines for their psychological and physical health 
requirements, since they cannot afford the products of western pharmaceutical 
industries(Salie et al., 1996), together with their side effects and lack of healthcare 
facilities. Rural areas of many developing countries still rely on traditional 
medicines for their primary health care needs and have found a place in day-to-day 
life. These medicines are relatively safer and cheaper than synthetic or modern 
medicine (Iwu et al., 1996; Idu et al.,2007). People living in rural areas from their 
personal experience known that these traditional medicines are valuable source of 
natural products to maintain human health, but they may not understand the science 
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behind these medicines, but knew that some medicinal plants are highly effective 
only when used at therapeutic doses (Maheswari et al., 1986). 
Medicinal plants are assuming greater importance in the primary health care of 
individuals and communities in many developing countries. Indian medicinal plants 
and their derivatives have been an invaluable source of therapeutic agents to treat 
various disorders. Herbal products are often perceived as safe because they are” 
natural”. In recent years herbal medicine is a major component in all traditional 
medicine system, and a common element in Siddha, Ayurvedic, Homeopathic, 
Naturopathic, Traditional Chinese medicine, and Native American medicine. 
Considerable efforts have been directed towards the development of natural products 
from various plant sources(Hazeena Begum V et al.,2011). 
Today a substantial number of drugs are developed from plants which are 
active against a number of diseases. The majority of these involve the isolation of 
the active ingredient(chemical compound) found in a particular medicinal plant and 
its subsequent modification. In the developed countries 25 percent of the medical 
drugs are based on plants and their derivatives and the use of medicinal plants is 
well known among the indigenous people in rural areas of many developing 
countries(Ignacimuthu. S et al.,2009). 
Plants used in traditional medicines have stood up to the test of time and 
contributed many novel compounds for preventive and curative medicine to modern 
science. India is sitting on a gold mine of well recorded and traditionally well 
practiced knowledge of herbal medicine. Specially, plants growing at high altitude 
in Himalayan pastures are time-honored sources of health and general well-being of 
local inhabitants. As of today, Himalayan plants are a major contributor to the herbal 
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pharmaceutical industry both of India and other countries.Plants growing at higher 
altitude are subjected to an assault of diverse testing situations including higher 
doses of mutagenic UV-radiation, physiological drought, desiccation and strong 
winds. Plants interact with stressful environment by physiological adaptation and 
altering the biochemical profile of plant tissues and producing a spectrum of 
secondary metabolites. Secondary metabolites are of special interest to scientists 
because of their unique pharmacophores and medicinal properties. 
Secondary metabolites like polyphenols, terpenes and alkaloids have been 
reported to possess antimutagenic and anticancer properties in many studies. The 
fundamental aspiration of the current review is to divulge 
theantimutagenic/anticancer potential of five alpine plants used as food or medicines 
by the populations living at high altitudes. India is the largest producer of medicinal 
plants and is rightly called the “Botanical garden of the World”. The medicinal 
plants, besides having natural therapeutic values against various diseases, also 
provide high quality of food and raw materials for livelihood. Considerable works 
have been done on the traditional uses and scientific reports. These plants may 
promote host resistance against infection by re-stabilizing body equilibrium and 
conditioning the body tissues. Several reports describe that the anticancer activity of 
medicinal plants is due to the presence of antioxidants in them. In fact, the medicinal 
plants are available, cheaper and possess easily no toxicity as compared to the 
modern (allopathic) drugs. Hence, this review article contains 66 medicinal plants, 
which are the natural sources of anticancer agents.  
The rediscovery of Ayurveda is a sense of redefining it is modern medicines. 
Emerging concept of combining Ayurveda with advanced drug discovery 
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programme is globally acceptable. Traditional medicine has a long history of serving 
peoples all over the world. The ethnobotany provides a rich resource for natural drug 
research and development. In recent years, the use of traditional medicine 
information on plant research has again received considerable interest. The Western 
use of such information has also come under increasing scrutiny and the national 
and indigenous rights on these resources have become acknowledge by most 
academic and industrial researchers. According to the World Health 
Organization(WHO), about three quarters of the world’s population currently use 
the herbs and other forms of traditional medicines to treat diseases. Traditional 
medicines are widely use d in India. (Debjit Bhowmik et al.,2013) 
A survey of current pharmaceutical use revealed that, of the total 
ptrescription drugs dispensed, 25% are plant derived (Farnsworth and Morris, 1976). 
Plant comopounds are highly varied in structure ; many are aromatic substances, 
most of which are phenols or their oxygen substituted derivatives. However, there is 
an increased attention on extracts and biologically active compounds isolated from 
plant species used in herbal medicine, due to the side effects and the resistance the 
pathogenic micro organism build against the antibiotics(Essawi and Srour, 1999). 
New compounds inhibiting micro organisms such as benzoin and emetine have been 
isolated from plants. Of the various pharmaceuticals used in modern medicine, 
atropine, ephedrine, digoxin, morphine, quinine, reserpine and tubocurarine serve as 
examples of drugs discovered through observations of indigenous medical practice 
(Gilani and Rahman,2005). 
Plant constituents may be isolated andused directly as therapeutic agents or 
as starting materials for drug synthesis or they may serve as model for 
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pharmacologically active compounds in drug synthesis. The general research 
methods includes proper selection of medicinal plants, preparation of crude extracts, 
biological screening, detailed chemo pharmacological investigations, toxicological 
and clinical studies, standardization and use of active moiety as the lead molecule 
for drug design(Wink et al.,2005). 
1.2. HERBAL PLANTS 
 Herbal drugs referred as plants materials or herbalism, involves the use of 
whole plants or parts of plants, to treat injuries or illness. Herbal drugs are use of 
therapeutic herbs to prevent and treat diseases and ailments or to support health and 
healing. These are drugs or preparations made from a plant and used for any of such 
purposes. Herbal drugs are the oldest form of health care known to mankind. They 
are many herbal products offered that assert to treat the symptoms of a broad range 
of problems, from depression to cold and flu. World Health Organization (WHO) 
has distinct herbal drugs as complete, labeled medicinal products that have various 
ingredients, aerial or secretive parts of the plants or other plant material or 
combinations. World Health Organization has set precise guidelines for the 
evaluation of the safety, efficacy, and quality of herbal medicines. 
 WHO estimates that 80% of the world populations currently use herbal drugs 
for major health care. Exceptionally, in some countries herbal drugs may also 
enclose by tradition, natural organic or inorganic active constituents which are not of 
plant source. Herbal drug is a chief constituents in traditional medicine and common 
constituents in Ayurvedic, Homeopathic, Naturopathic, and other medicine systems. 
Herbs are usually considered as safe since they belongs to natural sources. The use 
of herbal drugs due to toxicity and side effects of Allopathic medicines, has led to 
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rapid increase in the number of herbal drug manufacturers. For the past few decades, 
herbal drugs have been more and more consumed by the people with no 
prescription. 
 Seeds, leaves, stem, bark, roots, flowers, and extracts of all of these have 
been used in herbal drugs over the millennia of their use. Herbal products have 
reached extensive adequacy as beneficial agents like anti microbial, anti diabetic, 
anti fertility, anti aging, anti arthritic, sedative, anti depressant, anti anxiety, anti 
spasmodic, analgesic, anti inflammatory, anti-HIV, vasodilatory, hepatoprotective, 
treatment of cirrhosis, asthma, acne, impotence, menopause, migraine, gall stones, 
chronic fatigue, Alzheimer’s disease and memory enhancing activities. Herbal drugs 
have been recognized for approximately 4000 years. These drugs have survived real 
world testing and thousands of years of human testing. Some drugs have been 
discontinued due to their toxicity, while other have been modified or combined with 
additional herbs to side effects.  
1.2.1 Advantages ofHerbal Drugs 
• Low/Minimum cost 
• Potency and efficiency 
• Enhanced tolerance 
• More protection 
• Fewer side-effects 
• Complete accessibility 
• Recyclable 
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1.2.2. Disadvantage of Herbal Drug 
• Not able to cure rapid sickness and accidents 
• Risk with self dosing 
• Complexity in standardizations. 
1.2.3. Usage and Preparation of Herbal Drugs 
The usage of herbal drugs in the correct Way provides effectual and safe 
treatment for many ailments. The efficiency of the herbal drugs is typically 
subjective to the patient. The strength of the herbal drugs varies based on the genetic 
distinction, growing conditions, timing and method of harvesting, revelation of the 
herbs to air, light and dampness, and type of conservation of the herbs. Some of the 
plants that make up herbal drugs are cultured and processed in the country and 
others are imported from around the world. Raw materials for herbal drugs may be 
derived from carefully cultivated plants or collected in the wild. Herbal drugs are 
accessible in several forms and often require preparation before their use. They can 
be normally purchased in mass form as dried plants, plant parts or insecurely packed 
for herbal teas and decoctions. Decoctions are made by boiling the herb in water, 
then straining out of the plant material. More intense form of herbal drugs are 
available in the form of hydro alcoholic tinctures and fluid extracts. Methods of 
preparation may differ because of the nature of the plants active chemical 
constituents.  
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1.2.4. Pharmacological Actions of Herbal Drugs 
1.2.4.1. Anti-inflammatory activity 
The extracts of Achillea millefolium, Artemisia vulgaris, Bauhinia 
tarapotensis, Curcuma longa, Forsythia suspense, Houttuynia cordata, Glycyrrhiza 
uralensis, Lonicera japonica, Ruta graveolens, Securidaca longipedunculata and 
Valeriana wallichii have shown anti-inflammatory activity. 
1.2.4.2. Anti diabetic activity 
From earliest period, people are using herbal plants as home remedies for the 
treatment of diabeties. A  variety of herbal plants with anti diabetic activity are 
Abroma augusta, Acacia melanoxylon, Acacia modesta, Acacia nilotica, Aconitum 
ferox, Adatoda vasika, Adiantum capillus, Adiantum incisum, Agrimonia eupatoria, 
Allium sativum, Aloe barbadensis, Althae officinalis, Apium graveolens, Arcitium 
lappa, Commiphora abyssinca, Embilica officinalis, Eucalyptus globules, Ginseng 
panax, Gymnema sylvestre, Inula helenium, Juniperus communis, Medicago sativa, 
Orthosiphon stamineus, Panex quinquefolius, Polygala senega, Plantago 
ovata,Punica granatum, Salvia officinalis, Scoparia dulcis, Tanacetum vulgare, 
Taraxacum officinale, Tecoma stans, Trifolium alexandrium, Trigonella foenum, 
Turnera diffusa,. 
1.2.4.3. Analgesic activity 
The extracts of Bougainvilla spectabilis, Chelidonium majus, Ficus 
glomerata, Dalbergia lanceolaria, Glacium paucilobum, Nepeta italic, Polyalthia 
longifolia, Sida acuta, Stylosanthes fruiticosa, Toona ciliate, Zataria multiflora, and 
Zingiber zerumbet are used as analgesic agents. 
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1.2.4.4. Anticancer activity 
  Medicinal plant products exhibiting anticancer activity continue to be the 
subject of extensive research aimed at the development of drugs for the treatment of 
different human tumors. The medicinal plants used for the treatment of cancer 
are,Acalypha fruiticosa, Alangium lamarki, Catharanthus roseus, Celastrus 
paniculatus, Embelica ribes, Ficus glomerata, Terminalia chebula, Tylophora 
indica, The extracts used for the treatment of breast  cancer are Buthus martensi, 
Colla cornu, Herba epimedi, Radix glycyrrhizae, Squama manitis, Tuber curcumae, 
The herbal drugs used for the treatment of pancreatic cancer  are Embilica officnalis, 
Nigella sativa, and Terminalia belleric. 
1.2.4.5. Anti- ageing activity 
Cell membranes are particularly susceptible to the hostility of free radicals. 
When the nucleus is injured, the cell loses its ability to replicate itself. The impaired 
cell replication results in the destabilized immune system, skin ageing and may age 
related disorders. Various antioxidants neutralize the free radicals and prevent 
oxidation on a cellular level.The most effectual antioxidants include pine bark 
extract, grape seed extracts, and blue berries were effectual against the hostility of 
free radicals. Some commonly used herbs as anti-ageing agents areAllium sativum, 
Arnica Montana, Cucumis sativum, Curcuma longa, Ocimum sanctum, Panax 
ginseng, Rosa damascence and Withania somnifera.  
1.2.4.6. Antifertility activity 
of naturally occurring fertility regulating agent because of their little or no 
side effects. The plants that have been reported to have anti fertility activity are 
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Amaranthus retroflexus ,Artabotrys odoratissimus ,Barberis vulgarios, Carica 
papaya, Dieffenbachia seguine, Evodia rutacapra, Fatsia horrid, Ferula 
assafoetida, Hibiscus rosasinensis, Lonicera ciliosa, Magnolia virginiana, 
Mardenia cundurango, Pisum sativum, Podophyllum peltatum, Punica granatum, 
Raphanus sativus, Rehmannia glutinosa, Semecarpus anacardium, Sesbania sesban, 
Thuja occidentalis, Taxus baccata, and Verbena officinalis. 
1.2.4.7. Anti-psoriasis activity 
A variety of natural proprietary formulas and preparations containing plant 
materials have been used to provide symptomatic relief in psoriasis. The different 
herbal  remedies for psoriasis are, turmeric,curcurmin, shark cartilage extract, 
oregano oil, milk thistle. Various antimicrobial agents Azardirachta indica, 
Calendula officinalis, Cassia tora, Wrightia tinctoria have been used in the 
management of psoriasis. 
1.2.4.8. Anti depressant activity 
A number of nutritional and herbal supplements have shown promise as 
alternative treatment for depression. A large number of plants have potential 
functions to treat depression which are described as, Bacopa monniera, Panax 
quinquefolius, Piper methysticum, Rhodiola rosea, Valerina officianalis and 
Hypericum perforatum. 
1.2.4.9. Anti vitiligo activity 
Anti vitiligo oil is a herbal remedy manufactured with potent herbs and is 
produced with traditional methods and is also a complete traditional herbal 
formulation. The plants which can be used in the treatment of vitiligo are Acorus 
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calamus, Adiantum capillus, Bowellia serrate, Cassia angustifolia, Cassia tora, 
Cinnamom cassia, Fumaria officinalis, Glycyrhiza glabra, Lavandula stoechas, 
Rosa damascene, Vitis vinifera, Zingiber officinale and Zizyphus sativa. 
1.2.4.10. Treatment of dental diseases 
The plant having the dental care properties are Acacia catechu,Acacia 
arabica,Althea officinalis, Anacylus pyrethrum, Azardirachta indica, Barleria 
prionits, Cinnamomum camphora, Cuminum cyminum, Eucalyptus globules, 
Gardenia gummifera, Holarrhenia antidysentrica, Jasmimum grandiflorum, Juglans 
regia, Myrica sapida, Ocimum sanctum, Origanum vulgare, piper longum, piper 
nigrum, Salvadora persica, Saliva officinalis, Thalictrum foliolosum and 
Zanthoxylum alatum. All these regimens play an important role in suppressing the 
dental problems. 
1.2.5. Standardization of Herbal Drugs 
Herbal drugs imply knowledge and practice of herbal healing for the 
prevention, diagnosis, and elimination of physical, mental, or social imbalance. The 
costs for healthcare are rising at an alarming rate throughout the world. At the same 
time, the world market for phytopharmaceuticalsis growing progressively. The 
world Bank estimates that trade in medicinal plants, botanical drug products, and 
raw materials are growing at an annual rate of between 5 and 15 %. It is a common 
observation that people diagnosed with incurable chronic disease states such as 
diabetes, arthritis, and AIDS turned to herbal therapies for a sense of control and 
mental comfort from taking action. Herbal product studies cannot be considered 
scientifically valid if the product tested has not been authenticated and characterized 
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in order to ensure reproducibility in the manufacturing of the product in question. 
Several studies have indicated quantitative variations in marker constituents in 
herbal preparations.  
Moreover, many dangerous and lethal side effects have recently been 
reported, including direct toxic effects, allergic reactions, effects from contaminants, 
and interactions with drugs and other herbs. The 10 most commonly used herbs in 
the United States, systematic reviews have concluded that only 4 are likely to be 
effective and there is very limited evidence to evaluate the efficacy of the 
approximately 20,000 other available herbal products. Standardized herbal products 
of consistent quality and containing well-defined constituents are required for 
reliable clinical trials and to provide consistent beneficial therapeutic effects. 
Pharmacological properties of an herbal formulation depend on phytochemical 
constituents present therein. Development of authentic analytical methods which can 
reliably profile the phytochemical composition, including qualitative analyses of 
marker/bioactive compounds and the other major constituents, is a major challenge 
to scientists. Without consistent quality of a phytochemical mixture, a consistent 
pharmacological effectsis not expected. Resurgence of interest and the growing 
market of herbal medicinal products necessitate strong commitment by the 
stakeholders to safeguard the consumer and the industry. Standardization is the first 
step for the establishment of a consistent biological activity, a consistent chemical 
profile, or simply a quality assurance program for production and manufacturing. 
Therefore, the EU has defined three categories of herbal products: 
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• Those containing constituents (single compounds or families of compounds) 
with known and experienced therapeutic activity that are deemed solely 
responsible for clinical efficacy. 
• Those containing chemically defined constituents possessing relevant 
pharmacological properties which are likely to contribute to the clinical efficacy. 
• Those in which no constituents have been identified as being responsible for the 
therapeutic activity. 
Standardization as defined in the text for guidance on the quality of herbal 
medicinal products means adjusting the herbal drug preparation to a defined content 
of a constituents or group of substance with known therapeutic activity. The 
European Medicines Agency (EMEA) makes the distinction between constituents 
with known therapeutic activity which can be used to standardize a biological effect 
and marker compounds which allow standardization on a set amount of the chosen 
compound. The EMEA define marker compounds as chemically defined 
constituents of a herbal drug which are of interest for control purposes, independent 
of whether they have any therapeutic activity or not. Examples of markers are the 
valernic acids in Valeriana officinalis L., gingkolides and flavonoids in Ginko 
biloba L., and hypertension in Hypericum perfoliatum L., 
1.2.6. Stability testing of Herbal Drugs 
Stability testing of herbal drugs is a challenging risk, because the entire herb 
or herbal products is regarded as the active matter, regardless of whether 
constituents with defined therapeutic activity are known. The purpose of a stability 
testing is to provide proof on how the quality of the herbal products varies with the 
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time under the influence of environmental factors such as temperature, light, 
oxygen, moisture, other ingredients or excipients in the dosage form, particle size of 
drug, microbial contamination, trace metal contamination, leaching from the 
container and to establish a recommended storage condition and shelf-life. Stability 
testing is necessary to ensure that the product is of satisfactory quality throughout its 
entire storage period. Stability studies should be performed on at least three 
production batches of the herbal products for the proposed shelf life, which is 
normally denoted as long term stability and is performed under natural atmospheric 
conditions. Stability data can also be generated under accelerated atmospheric 
condition of temperature, humidity and light, which is referred to as short term 
stability and the data so obtained is used for predicting shelf-life of the product. 
Stability testing should be conducted on the dosage form packaged in the container 
closure system proposed for marketing. With the help of modern analytical 
technique like spectrophotometry, HPLC, HPTLC and by employing proper 
guidelines it is possible to generate a sound stability data of herbal products and 
predict their shelf-life, which will help in improving global acceptability of herbal 
products (Bodhisattwa Maiti et al.,2011 ). 
1.4. PHYTOCONSTITUENTS AND ITS ACTIONS 
1.4.1. Alkaloids: 
Alkaloids are derived from plant sources, they are basic, they contain one or 
more nitrogen atoms (usually in a heterocyclic ring) and they usually have a marked 
physiological action on man or other animals. 
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Alkaloids are mainly used as antitumor (vincristine,vinblastin), anti- 
cholinergic (atropine), stimulant(caffeine), antimalarial and antipyretic (quinine), 
cough medicine and analgesic (codein) etc…. 
1.4.2.Flavonoids: 
Flavonoids are the largest class of polyphenols. Chemically, they may be 
defined as a group of polyphenolic compounds consisting of substance that have two 
substituted benzene rings connected by the chain of three carbon atoms and an 
oxygen bridge. 
Flavonoids possesanti-bacterial, anticancer, anti-inflammatory actions and 
used in the treatment of cardiovascular diseases. 
1.4.3. Glycosides: 
 Glycosides may be defined, in general, as the organic compounds from 
plantsor animal sources which on enzymatic or acid hydrolysis give one or more 
sugar (glycon) moieties along with non-sugar (aglycon) moiety. 
 Glycosides are used as cardio tonic, purgative, anti-rheumatic and analgesic, 
demulcent. 
1.4.4. Tannins: 
 Tannins are chemically defined as the mixture of complex organic substance 
where in polyphenols are present with O-dihydroxy or O-trihydroxy groups on a 
phenyl ring. 
 Tannins are used as mild antiseptic, in treatment of diarrhea and to forestall 
minor hemorrhage. 
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1.4.5. Carbohydrates: 
 Carbohydrates may be defined as polyhydroxy aldehyde or ketones or 
compounds which produce them on hydrolysis. 
Carbohydrates are mainly used as demulcent, laxative, anti-diarrheal, 
pharmaceutical agent etc…. 
1.4.6. Fixed oils and fats: 
These are the reverse food materials of plants and animals.Those, which are 
liquid at 15.5oC to 16.5oC are called as fixed oils; while those which are solid or 
semisolid at above temperature are termed as fats. Fixed oil is mainly used as 
rubifacient, counter irritant, laxative, and spermicidal, ointment base, suppository 
base etc…. 
1.4.7. Mucilage: 
 These are polysaccharide complexes of sugar and uronic acids, usually 
formed from the cell wall. They are insoluble in alcohol but swell or dissolve in 
water. 
They are used as emulsifiers, suspending agent, demulcent etc… 
1.4.8. Proteins and amino acids: 
 Proteins are complex nitrogenous organic substances of plant and animal 
origin. They are of great importance in the functioning of living cells. They contain 
carbon, hydrogen, oxygen, nitrogen and rarely sulfur.The ultimate products of 
complete hydrolysis of proteins, either by chemical reagents or enzymes, are amino 
acids. 
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Amino acids are group of organic compounds containing two functional 
groups-amino and carboxyl. The amino group is basic while the carboxyl group is 
acidic in nature. 
Proteins are mainly used as digest ant, anti-inflammatory agent, 
anticoagulant,nutritive,dietary supplement (Kokatae et al.,2012).  
1.5. INTRODUCTION TO DIABETES 
1.2.1. History of diabetes mellitus 
 The earliest description of diabetes was documented in the writings of Hindu 
scholars as long as in 1500 BC. They had already described “a mysterious disease 
causing thirst, enormous urine output, and wasting away of the body with flies and 
ants attracted to the urine of people.” 
 The term diabetes was probably coined by Apollonius of Memphis around 
250 BC, which literally meant “to go through” or siphon as the disease drained more 
fluid than a person could consume. Later on, the Latin word “mellitus” was added 
because it made the urine sweet.  (MacCracken J. 1997). 
Sushruta, Arataeus, and Thomas Willis were the early pioneers of the 
treatment of diabetes. Greek physicians prescribed exercise, preferably on 
horseback, to “employ moderate friction” and alleviate excess urination. Wine, 
overfeeding to compensate for loss of fluid weight, starvation diet, potato therapy, 
and oat cure were some of the other curious forms of remedy suggested for the 
therapy of diabetes in olden days (MacCracken J.1997). 
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Sir William Osler, in the year 1915, is said to have even recommended 
opium! Early research linked diabetes to glycogen metabolism, and the islet cells of 
pancreas were discovered by Paul Langerhans, a young German medical student. In 
1916, Sharpey-Shafer of Edinburgh suggested that a single chemical was missing 
from the pancreas and proposed its name as “insulin.” The term insulin originates 
from the word Insel, which is German for an islet or island. 
Researchers like E.L. Scott and NikolaePaulesco were successful in 
extracting insulin from the pancreas of experimental dogs. The key breakthrough, 
though, came from the Toronto University with the discovery of insulin in 1921. FG 
Banting and JJR Macleod were awarded the Nobel Prize for Physiology or Medicine 
in 1923 (Bliss M.1982.).   
1.2.2. Definition of Diabetes mellitus 
 Diabetes mellitus is a group of metabolic diseases characterized by chronic 
hyperglycemia resulting from defects in insulin secretion, insulin action, or both. 
The abnormalities in carbohydrate, fat, and protein metabolismthat are found in 
diabetes are due to deficient action of insulin on target tissues. 
 If ketones are present in blood or urine, treatment is urgent, because 
ketoacidosis can evolve rapidly(American diabetes association,2001). 
1.2.3.Causes 
 Diabetes is a chronic disease that occurs when the pancreas does not produce 
enough insulin, or alternatively, when the body cannot effectively use the insulin it 
produces. Insulin is a hormone that regulates blood sugar, hyperglycemia, or raised 
blood sugar, is a common effect of uncontrolled diabetes and over time leads to 
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serious damage to many of the body’s systems, especially the nerves and blood 
vessels. 
1.2.4. Symptoms of diabetes mellitus 
 Common symptoms include the following: 
• Frequent urination 
• Excessive thirst 
• Unexplained weight loss 
• Extreme hunger 
• Sudden vision changes 
• Tingling or numbness in the hands or feet 
• Feeling very tired much of the time 
• Very dry skin 
• Sores that are slow to heal 
• More infections than usual 
 Some people may experience only a few symptoms that are listed above. 
About 50 percent of people with type 2 diabetes don't experience any symptoms and 
don't know they have the disease. (www.ucsfhealth.org)  
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1.2.5.Pathophysiology of diabetes mellitus 
 
Figure No: 1.Pathophysiology of diabetes mellitus 
1.3.CLASSIFICATION OF DIABETES MELLITUS 
Diabetes mellitus (or diabetes) is a chronic, lifelong condition that affects your 
body's ability to use the energy found in food. There are three major types of 
diabetes: type1diabetes, type 2diabetes, and gestational diabetes.(www.webmd.com) 
1.3.1. Type 1 diabetes mellitus:(β-cell destruction, usually leading to absolute 
insulin deficiency) 
Type 1 diabetes represents a heterogeneous and polygenic disorder, with a 
number of non-HLA loci contributing to disease susceptibility (Lernmark A,1998). 
Though this form of diabetes accounts for 5 to 10% of all diabetics, yet there is no 
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identified agent substantially capable of preventing this type of disease (Atkinson 
MA,2001). The WHO and the American Diabetics Association (WHO;1999 and 
ADA;2001) have proposed that type 1 diabetes can be divided into autoimmune/ 
immune-mediated diabetes (Type 1A) and idiopathic diabetes with β-cell 
obstruction (Type 1B). This type of diabetes mellitus requires exogenous insulin to 
prevent Diabetic ketoacidosis. 
1.3.2.Immune mediated diabetes 
This form of diabetes, previously encompassed by the terms insulin 
dependent diabetes, or juvenile-onset diabetes, results from a cellular-mediated 
autoimmune destruction of the β-cells of the pancreas.(American diabetes 
association,2012) 
 
 
Figure No: 2. Immune mediated diabetes 
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Type 1 diabetes is an autoimmune condition. It's caused by the body 
attacking its own pancreas with antibodies. In people with type 1 diabetes, the 
damaged pancreas doesn't make insulin. 
This type of diabetes may be caused by a genetic predisposition. It could also 
be the result of faulty beta cells in the pancreas that normally produce insulin. 
A number of medical risks are associated with type 1 diabetes. Many of them 
stem from damage to the tiny blood vessels in your eyes (called diabetic 
retinopathy), nerves (diabetic neuropathy), and kidneys (diabetic nephropathy). 
Even more serious is the increased risk of heart disease and 
stroke.(www.webmd.com) 
1.3.3. Idiopathic diabetes 
Some forms of type1 diabetes have no known etiologies. Some of these 
patients have permanent insulinopenia and are prone to ketoacidosis, but have no 
evidence of autoimmunity.Although only a minority of Patients with type 1 diabetes 
fall into this category, of those who do, most are of African or Asian ancestry. 
Individuals with this form of diabetes suffer from episodic ketoacidosis and 
exhibit varying degrees of insulin deficiency between episodes. This formof diabetes 
is strongly inherited, lacks immunological evidence for β-cell 
autoimmunity(Americandiabetes association,2012). 
Treatment for type 1 diabetes involves taking insulin, which needs to be 
injected through the skin into the fatty tissue below. (www.webmd.com) 
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1.3.4. Type 2 diabetes 
Type 2diabetes is far more common and results from a combination of 
defects in insulin secretion and insulin action, either of which may predominate. 
People with type 2 diabetes are not dependent on exogenous insulin, but may require 
it for the control of blood glucose levels if this is not achieved with diet alone or 
with oral hypoglycemic agents. This type of diabetes accounts for 90 to 95% of all 
diabetic patients (DeFronzo RA, 1997).  
All forms of diabetes are characterized by chronic hyperglycemia and the 
development of diabetes- specific micro vascular pathology in the retina, renal 
glomerulus, and peripheral nerve. As a consequence of its micro vascular pathology, 
diabetes is a leading cause of blindness, end-stage renal disease, and a variety of 
debilitating neuropathies.  
When islet b-cell function is impaired, insulin secretion is inadequate, 
leading to overproduction of glucose by the liver and under-utilization of glucose in 
peripheral tissue(Bergman RN et al, 1989). 
Type 2 diabetes is made up of different forms, each of which is characterized 
by a variable degree of insulin resistance and β-cell dysfunction and which together 
lead to hyperglycemia (American Diabetes Association,2001).  
At each end of this spectrum are single gene disorders that affect the ability 
of the pancreatic β cell to secrete insulin (Fajans SS et al,2001 and Owen K et 
al,2001) or the ability of muscle, fat, and linear cells to respond to insulin action 
(Taylor SI et al, 1999 and Barroso I et al, 1999). 
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Figure No: 3. Type 2 diabetes 
With Type 2 diabetes, the pancreas usually produces some insulin. But either 
the amount produced is not enough for the body's needs, or the body's cells are 
resistant to it. Insulin resistance, or lack of sensitivity to insulin, happens primarily 
in fat, liver, and muscle cells. 
People who are obese  more than 20% over their ideal body weight for their 
height are at particularly high risk of developing type 2 diabetes and its related 
medical problems. Obese people have insulin resistance. With insulin resistance, the 
pancreas has to work overly hard to produce more insulin. But even then, there is 
not enough insulin to keep sugars normal. (www.webmd.com) 
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There is no cure for diabetes. Type 2 diabetes can, however, be controlled 
with weight management, nutrition, and exercise. Unfortunately, type 2 diabetes 
tends to progress, and diabetes medications are often needed(www.webmd.com). 
1.3.5.Gestational Diabetes 
Diabetes that's triggered by pregnancy is called gestational diabetes 
(pregnancy, to some degree, leads to insulin resistance). It is often diagnosed in 
middle or late pregnancy. Because high blood sugar levels in a mother are circulated 
through the placenta to the baby, gestational diabetes must be controlled to protect 
the baby's growth and development. 
According to the National Institutes of Health, the reported rate of 
gestational diabetes is between 2% to 10% of pregnancies. Gestational diabetes 
usually resolves itself after pregnancy. Having gestational diabetes does, however, 
put mothers at risk for developing type 2 diabetes in later.  Up to 10% of women 
with gestational diabetes develop type 2 diabetes. It can occur anywhere from a few 
weeks after delivery to months or years later. 
With gestational diabetes, risks to the unborn baby are even greater than 
risks to the mother. Risks to the baby include abnormal weight gain before birth, 
breathing problems at birth, and higher obesity and diabetes risk later in life. Risks 
to the mother include needing a cesarean section due to an overly large baby, as well 
as damage to heart, kidney, nerves, and eye. 
Treatment during pregnancy includes, 
• Careful meal planning to ensure adequate pregnancy nutrients without excess fat 
and calories 
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• Daily exercise 
• Controlling pregnancy weight gain 
• Taking diabetes insulin to control blood sugar levels if 
needed(www.webmed.com) 
1.3.6.Other specific types of diabetes 
a) Genetic defects of the β-cell 
 Several forms of diabetes are associated with monogenetic defects in β-cell 
function. These forms of diabetes are frequently characterized by onset of 
hyperglycemia at an early age (generally before age 25 years). They are referred to 
as maturity onset diabetes of the young (MODY) and are characterized by impaired 
insulin secretion with minimal or no defects in insulin action. 
b) Genetic defects in insulin action 
There are unusual causes of diabetes that result from genetically determined 
abnormalities of insulin action. The metabolic abnormalities associated with 
mutations of the insulin receptor may range from hyperinsulinemia and modest 
hyperglycemia to severe diabetes. 
c) Diseases of the exocrine pancreas 
Any process that diffusely injures the pancreas can cause diabetes. Acquired 
processes include pancreatitis, trauma, infection, pancreatectomy, and pancreatic 
carcinoma. With the exception of that caused by cancer, damage to the pancreas 
must be extensive for diabetes to occur; adrenocarcinomas that involve only a small 
portion of the pancreas have been associated with diabetes. This implies a 
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mechanism other than simple reduction in β-cell mass. If extensive enough, cystic 
fibrosis and hemochromatosis will also damage β-cells and impair insulin secretion. 
d) Endocrinopathies 
Several hormones (e.g., growth hormone, cortisol, glucagon, epinephrine) 
antagonize insulin action.Excess amounts of these hormones (e.g.,acromegaly, 
Cushing’s syndromeglucagonoma, pheochromocytoma, respectively) can cause 
diabetes. This generally occurs in individuals with preexisting defects in insulin 
secretion, and hyperglycemia typically resolves when the hormone excess is 
resolved. 
e) Drug- or chemical-induced diabetes 
Many drugs can impair insulin secretion.These drugs may not cause diabetes 
bythemselves, but they may precipitate diabetes in individuals with insulin 
resistance.In such cases, the classification is unclear because the sequence or relative 
importance of β-cell dysfunction and insulin resistance is unknown. Certain toxins 
such as Vacor(a rat poison) and intravenous pentamidine can permanently destroy 
pancreatic β-cells. 
f) Infections 
Certain viruses have been associated with β-cell destruction. Diabetes occurs 
in patients with congenital rubella, although most of these patients have HLA and 
immune markers characteristic of type 1 diabetes. In addition, coxsackievirus B, 
cytomegalovirus, adenovirus, and mumps have been implicated in inducing certain 
cases of the disease.(American diabetes association,2012) 
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1.4.Evolution of insulin 
 Insulin is a natural hormone and as essential as air, water, and light. Amongst 
all the antidiabetic medications, it is the most potent agent that reduces blood 
glucose levels. Its benefits exceed beyond the realms of glycemic control. 
 It reduces glucotoxicity and lipotoxicity, reverses insulin resistance, 
preserves beta cell function, and it improves lipid profile, endothelial dysfunction, 
anti-inflammatory effects, and anti-platelet effects as well as the quality of life. In 
spite of all these benefits, there is an inherent clinical inertia before initiating insulin 
therapy, especially for patients with type 2 diabetes mellitus. (Galloway JA et 
al;1994.) 
1.4.1. Structure of insulin 
Insulin was purified and crystallized by Abel within a few years of its 
discovery. Sanger established the amino acid sequence of insulin in 1960, the 
protein was synthesized in 1963, and Hodgkin and coworkers elucidated insulin's 
three-dimensional structure in 1972. Insulin was the hormone for which Yalow and 
Berson first developed the radioimmunoassay (Kahn and Roth, 2004). 
Theβ cells of pancreatic islets synthesize insulin from a single-chain 
precursor of 110 amino acids termed preproinsulin. After translocation through the 
membrane of the rough endoplasmic reticulum, the 24-amino-acid N-terminal signal 
peptide of preproinsulin is cleaved rapidly to form proinsulin. Thereafter, proinsulin 
folds, and the disulfide bonds form. During conversion of human proinsulin to 
insulin, four basic amino acids and the remaining connector or C peptide are 
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removed by proteolysis. This gives rise to the A and B peptide chains of the insulin 
molecule, which contains one intra-subunit and two inter-subunit disulfide bonds. 
The A chain usually is composed of 21 amino acid residues, and the B chain 
has 30; the molecular mass is thus about 5734 daltons. Although the amino acid 
sequence of insulin has been highly conserved in evolution, there are significant 
variations that account for differences in both biological potency and 
immunogenicity (De Meyts, 1994) 
 
Figure No: 4. Structure of insulin 
There is a single insulin gene and a single protein product in most species. 
However, rats and mice have two genes that encode insulin and synthesize two 
molecules that differ at two amino acid residues in the B chain. 
The crystal structure reveals that the two chains of insulin form a highly 
ordered structure with a-helical regions in each of the chains. The isolated chains of 
insulin are inactive. 
In solution, insulin can exist as a monomer, dimer, or hexamer. Two 
molecules of Zn2+ are coordinated in the hexamer, and this form of insulin 
presumably is stored in the granules of the pancreatic β cell. It is believed that 
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Zn2+has a functional role in the hexamer formation and that this process facilitates 
the conversion of proinsulin to insulin and storage of the hormone. 
Traditional insulin is hexameric in most of the highly concentrated 
preparations used for therapy. When the hormone is absorbed and the concentration 
falls to physiological levels (nanomolar), the hormone dissociates into monomers, 
and the monomer is most likely the biologically active form of insulin. Monomeric 
insulin is now available for therapy.(Goodman and Gillman,2006) 
Insulin is a member of a family of related peptides termed insulinlike growth 
factors (IGFs). The two IGFs (IGF-1 and IGF-2) have molecular masses of about 
7500 daltons and structures that are homologous to that of proinsulin. However, the 
short equivalents of the C peptide in proinsulin are not removed from the IGFs. 
In contrast with insulin, the IGFs are produced in many tissues, and they may 
serve a more important function in the regulation of growth than in the regulation of 
metabolism. These peptides, particularly IGF-1, are the presumed mediators of the 
action of growth hormone, and they originally were called somatomedins. The 
uterine hormone relaxin also may be a distant relative of this family of polypeptides, 
although the relaxin receptor clearly is distinct from those for insulin and IGF-1. 
The receptors for insulin and IGF-1 are also closely related (Nakaeet al., 
2001). Thus, insulin can bind to the receptor for IGF-1 with low affinity and vice 
versa. The growth-promoting actions of insulin appear to be mediated in part 
through the IGF-1 receptor, and there may be discordance between the metabolic 
potency of an insulin analog and its ability to promote growth. 
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1.4.2.Synthesis of Insulin 
Like other peptide hormones insulin is synthesized as a precursor 
(preproinsulin) in the rough endoplasmic reticulum. Preproinsulin is transported to 
the Golgi apparatus, where it undergoes proteolytic cleavage first to proinsulin and 
then to insulin plus a fragment of uncertain function called C-peptide.1 
Insulin and C-peptide are stored in granules in  cells, and are normally 
cosecreted by exocytosis in equimolar amounts together with smaller and variable 
amounts of proinsulin. The main factor controlling the synthesis and secretion of 
insulin is the blood glucoseconcentration.cells respond both to the absolute 
glucose concentration and to the rate of change of blood glucose. 
Other stimuli to insulin release include amino acids (particularly arginine and 
leucine), fatty acids, the parasympathetic nervous system, peptide hormones for the 
gut and drugs that act on sulfonylurea receptors. 
There is a steady basal release of insulin and also a response to an increase in 
blood glucose. This response has two phases: an initial rapid phase reflecting release 
of stored hormone, and a slower, delayed phase reflecting both continued release of 
stored hormone and new synthesis (Bolli G B et al 2000). 
1.4.3.Regulation of Insulin Secretion 
Insulin secretion is a tightly regulated process designed to provide stable 
concentrations of glucose in blood during both fasting and feeding. This regulation 
is achieved by the coordinated interplay of various nutrients, gastrointestinal 
hormones, pancreatic hormones, and autonomic neurotransmitters. Glucose, amino 
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acids, fatty acids, and ketone bodies promote the secretion of insulin. The islets of 
Langerhans are richly innervated by both adrenergic and cholinergic nerves. 
Stimulation of α2 adrenergic receptors inhibits insulin secretion, whereas β2 
adrenergic receptor agonists and vagal nerve stimulation enhance release. In general, 
any condition that activates the sympathetic branch of the autonomic nervous system 
(such as hypoxia, hypoglycemia, exercise, hypothermia, surgery, or severe burns) 
suppresses the secretion of insulin by stimulation of α2 adrenergic receptors. 
Predictably, α2 adrenergic receptor antagonists increase basal concentrations of 
insulin in plasma, and β2 adrenergic receptor antagonists decrease them.(Goodman 
and Gillman,2006) 
 
Figure No: 5. Regulation of Insulin Secretion 
1.4.4.Distribution and Degradation of Insulin 
 Insulin circulates in blood as the free monomer, and its volume of 
distribution approximates the volume of extracellular fluid. Under fasting 
conditions, the pancreas secretes about 40 mg (1 unit) of insulin per hour into the 
portal vein to achieve a concentration of insulin in portal blood of 2 to 4 ng/ml (50 
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to 100 min/ml) and in the peripheral circulation of 0.5 mg/ml (12 minuits/ml) or 
about 0.1 nm. 
 After ingestion of a meal, there is a rapid rise in the concentration of insulin 
in portal blood, followed by a parallel but smaller rise in the peripheral circulation. 
A goal of insulin therapy is to mimic this pattern, but this is difficult to achieve with 
subcutaneous injections. 
 The half-life of insulin in plasma is about 5 to 6 minutes in normal subjects 
and patients with uncomplicated diabetes. This value may be increased in diabetics 
who develop anti-insulin antibodies.  
 Degradation of insulin occurs primarily in liver, kidney, and muscle . About 
50% of the insulin that reaches the liver via the portal vein is destroyed and never 
reaches the general circulation. Insulin is filtered by the renal glomeruli and is 
reabsorbed by the tubules, which also degrade it.  
 Severe impairment of renal function appears to affect the rate of 
disappearance of circulating insulin to a greater extent than does hepatic disease. 
Hepatic degradation of insulin operates near its maximal capacity and cannot 
compensate for diminished renal breakdown of the hormone. Peripheral tissues such 
as fat also inactivate insulin, but this is of less significance quantitatively (Goodman 
and Gillman,2006). 
1.4.5.Mechanism of Insulin 
 Insulin binds to a specific receptor on the surface of its target cells. The 
receptor is a large trans-membrane glycoprotein complex belonging to the kinase-
linked type 3 receptor super families and consisting of two α and two β subunits. 
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Occupied receptors aggregate into clusters, which are subsequently internalized in 
vesicles, resulting in down-regulation. Internalized insulin is degraded in lysosomes, 
but the receptors are recycled to the plasma membrane. 
• The signal transduction mechanisms that link receptor binding to the biological 
effects of insulin are complex. Receptor autophosphorylation -the first step in 
signal transduction-is a consequence of dimerization, allowing each receptor to 
phosphorylate the other.  
• Insulin receptor substrate (IRS) proteins undergo rapid tyrosine phosphorylation 
specifically in response to insulin and insulin-like growth factor-1 but not to 
other growth factors. The best characterized substrate is IRS-1, which contains 
22 tyrosine residues that are potential phosphorylation sites. 
• It interacts with proteins that contain a so-called SH2 domain, thereby passing 
on the insulin signal. Knockout mice lacking IRS-1 are hypo responsive to 
insulin (insulin-resistant) but do not become diabetic because of robust B-cell 
compensation with increased insulin secretion. By contrast, mice lacking IRS-2 
fail to compensate and develop overt diabetes, implicating the IRS-2 gene as a 
candidate for human type 2 diabetes.  
• Activation of phosphatidylinositol 3-kinase by interaction of its SH2 domain 
with phosphorylated IRS has several important effects, including recruitment of 
insulin-sensitive glucose  transporters (Glut-4) from the Golgi apparatus to the 
plasma membrane in muscle and fat cells.  
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• The longer-term actions of insulin entail effects on DNA and RNA, mediated 
partly at least by the Rassignalling complex. Ras is a protein t growth and cycles 
between an active GTP-bound form and an inactive GDP-bound form. 
• Insulin shifts the equilibrium in favor of the active form, and initiates a 
phosphorylation cascade that results in activation of mitogen-activated protein 
kinase, which in turn activates several nuclear transcription factors, leading to 
the expression of genes that are involved both with cell growth and with 
intermediary metabolism. Regulation of the rate of mRNA transcription by 
insulin provides an important means of modulating enzyme activity. (rang and 
dale) 
1.4.6.Cellular action of Insulin 
 Insulin is the main hormone controlling intermediary metabolism, having 
actions on liver, muscle and fat. It is an anabolic hormone: its overall effect is to 
conserve fuel by facilitating the uptake and storage of glucose, amino acids  and 
fats after a meal. Acutely, it reduces blood sugar. Consequently, a fall in plasma 
insulin increases blood glucose. The biochemical pathways through which insulin 
exerts its effects and molecular aspects of its mechanism are discussed below. 
1.4.7.Effect of insulin on Carbohydrate metabolism 
Insulin influences glucose  metabolism in most tissues, especially the liver, 
where it inhibits glycogenolysis (glycogen breakdown) and gluconeogenesis 
(synthesis of glucosefrom non-carbohydrate sources) while stimulating glycogen 
synthesis. It also increases glucose utilization (glycolysis), but the overall effect is to 
increase hepatic glycogen stores. 
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In muscle, unlike liver, uptake of glucose  is slow and is the rate-limiting 
step in carbohydrate metabolism. The main effects of insulin are to increase 
facilitated transport of glucose via a transporter called Glut-4, and to stimulate 
glycogen synthesis and glycolysis. 
Insulin increases glucose  uptake by Glut-4 in adipose tissue as well as in 
muscle, enhancing glucoseol, which is esterifies with fatty acids to form 
triglycerides, thereby affecting fat metabolism metabolism. One of the main end 
products of glucose metabolism in adipose tissue is glycerol, which is esterifies with 
fatty acids to form triglycerides, thereby affecting fat metabolism. 
1.4.8.Effect of insulin on fat metabolism 
Insulin increases synthesis of fatty acid and triglyceride in adipose tissue and 
in liver. It inhibits lipolysis, partly via dephosphorylation (and hence inactivation) of 
lipases. It also inhibits the lipolytic actions of adrenaline, growth hormone and 
glucagon by opposing their actions on adenylatecyclase. 
1.4.9.Effect of insulin on protein metabolism 
 Insulin stimulates uptake of amino acids  into muscle and increases protein 
synthesis. It also decreases protein catabolism and inhibits oxidation of amino 
acidsin the liver. 
1.4.10.Other metabolic effect of insulin 
 Other metabolic effects of insulin include transport into cells of K+,3 Ca2+, 
nucleosides and inorganic phosphate  
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1.4.11.Long term effect of insulin 
 In addition to its rapid effects on metabolism, exerted via altered activity of 
enzymes and transport proteins, insulin has long-term actions via altered enzyme 
synthesis. It is an important anabolic hormone during fetal development. It 
stimulates cell proliferation and is implicated in somatic and visceral growth and 
development. 
 
Figure No: 6. Long term effect of insulin 
1.4.12.Insulin administration 
 Because insulin is a polypeptide, it is degraded in the gastrointestinal tract if 
taken orally. It therefore is generally administered by subcutaneous injection. [Note: 
In a hyperglycemic emergency, regular insulin is injected intravenously.] 
Continuous subcutaneous insulin infusion has become popular, because it does not 
require multiple daily injections. 
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Insulin preparations vary primarily in their times of onset of activity and in 
their durations of activity. This is due to differences in the amino acid sequences of 
the polypeptides. Dose, site of injection, blood supply, temperature, and physical 
activity can affect the duration of action of the various preparations. Insulin is 
inactivated by insulin-degrading enzyme (also called insulin protease), which is 
found mainly in the liver and kidney.  
1.4.13.Adverse reactions to insulin 
The symptoms of hypoglycemia are the most serious and common adverse 
reactions to an overdose of insulin. Long-term diabetics often do not produce 
adequate amounts of the counter-regulatory hormones (glucagon, epinephrine, 
cortisol, and growth hormone), which normally provide an effective defense against 
hypoglycemia. Other adverse reactions include weight gain, lipodystrophy (less 
common with human insulin), allergic reactions, and local injection site reactions. 
Diabetics with renal insufficiency may require adjustment of the insulin dose. 
1.5. Consequences of diabetes mellitus 
People living with diabetes may have to deal with short-term or long-term 
complications as a result of their condition. 
• Short-term complications include hypoglycaemia diabetic ketoacidosis (DKA), 
and hyperosmolar hyperglycaemic state (HHS). 
• Long-term complications include how diabetes affects your eyes (retinopathy), 
heart (cardiovascular disease), kidneys (nephropathy), and nerves and feet 
(neuropathy). 
Chapter 1 Introduction 
Department of Pharmacology           39 JKKMMRFCollege of Pharmacy 
1.5.1.Acute complications 
These include diabetic keto acidosis (DKA) and non-ketotic hyper-osmolar 
state (NKHS). While the first is seen primarily in individuals with type 1 DM, the 
latter is prevalent in individuals with type 2 DM. Both disorders are associated with 
absolute or relative insulin deficiency, volume depletion, and altered mental state. 
1.5.2.Chronic complications 
 The chronic complications of diabetes mellitus affect many organ systems 
and are responsible for the majority of morbidity and mortality. Chronic 
complications can be divided into vascular and nonvascular complications. The 
vascular complications are further subdivided into microvascular (retinopathy, 
neuropathy, and nephropathy) and macrovascular complications (coronary artery 
disease, peripheral vascular disease, and cerebrovascular disease). Nonvascular 
complications include problems such as gastroporesis, sexual dysfunction, and skin 
changes. 
➢ Diabetic retinopathy 
 Diabetic retinopathy occurs in 3/4 of all persons having diabetes for more 
than 15 years and is the most common cause of blindness. There is appearance of 
retinal vascular lesions of increasing severity, culminating in the growth of new 
vessels. 
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Figure No: 7. Diabetic retinopathy 
 Diabetic retinopathy is classified into two stages: non proliferative and 
proliferative. 
 The non-proliferative stage is marked by retinal vascular microneurisms, 
blotshemorrhages and cotton-wool spots and includes loss of retinal pericytes, 
increased retinal vascular permeability and alterations in regional blood flow, and 
abnormal retinal microvasculature, all of which lead to retinal ischemia. 
 In proliferative retinopathy there is the appearance of neovascularization in 
response to retinal hypoxia. The newly formed vessels may appear at the optic nerve 
and/or macula and rupture easily, leading to vitreous hemorrhage, fibrosis, and 
ultimately retinal detachment (Aiello LP et al,1998). 
➢ Neuropathy 
 About half of all people with diabetes have some degree of neuropathy, 
which can be polyneuropathy, mono-neuropathy and/or autonomic neuropathy.  
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 In polyneuropathy there is loss of peripheral sensation which, when coupled 
with impaired microvascular and macrovascular junction in the periphery,can 
contribute to non-healing ulcers, the leading cause of non-traumatic amputation. 
There is thickening of axons, decrease in microfi laments, and capillary narrowing 
involving small myelinated or non-myelinated C-fi bers. 
 It can occur both from direct hyperglycemia-induced damage to the nerve 
parenchyma and from neuronal ischemia leading to abnormalities of microvessels, 
such as endothelial cell activation, pericyte degeneration, basement membrane 
thickening, and monocyte adhesion. 
 Mono-neuropathy is less common than polyneuropathy and includes 
dysfunction of isolated cranial or peripheral nerves. Autonomic neuropathy can 
involve multiple systems, including cardiovascular, gastrointestinal, genitourinary, 
sudomotor, and metabolic systems (Chen YD et al, 1997). 
➢ Nephropathy 
This is a major cause of end-stage renal disease. There are glomerular 
hemodynamic abnormalities resulting in glomerular hyper-filtration, leading to 
glomerular damage as evidenced by microalbuminurea. There is overt proteinuria, 
decreased glomerular filtration rate, and end-stage renal failure. 
 Dysfunction of the glomerular filtration apparatus is manifested by 
microalbuminurea and is attributed to changes in synthesis and catabolism of 
various glomerular basement membrane macromolecules such as collagen and 
proteoglycans, leading to an increase in glomerular basement thickening. 
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 Another possible mechanism to explain the increase in permeability of   the 
glomerulus is the increase in renal VEGF levels, since VEGF is both an angiogenic 
and a permeability factor (Ritz E et al,1999). 
➢ Cardiovascular morbidity and mortality 
In diabetes mellitus there is marked increase in several cardiovascular 
diseases, including peripheral vascular disease, congestive heart failure, coronary 
artery disease, and myocardial infarction, and a one- to fivefold increase in sudden 
death. The absence of chest pain (silent ischemia) is common in individuals with 
diabetes, and a thorough cardiac evaluation is indicated in individuals undergoing 
major surgical procedures. 
Despite proof that improved glycemic control reduces microvascular 
complications in diabetes mellitus, it is possible that macrovascular complications 
may be unaffected or even worsened by such therapies. 
An improvement in the lipid profiles of individuals in the intensive group 
(lower total and low-density lipoprotein cholesterol, lower triglycerides) suggested 
that intensive therapy may reduce the risk of cardiac vascular mortality. 
In addition to coronary artery disease, cerebrovascular disease is increased in 
individuals with diabetes mellitus (threefold increase in stroke). 
Individuals with DM have increased incidence of congestive heart failure 
(diabetic cardiomyopathy). The etiology of this abnormality is probably 
multifactorial and includes factors such as myocardiac ischemia 
fromatherosclerosis,hypertension, and myocardial cell dysfunction secondary to 
chronic hyperglycemia. 
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Though DM itself does not increase levels of LDL, LDL particles found in 
type 2 DM are more atherogenic and are more easily glycated and susceptible to 
oxidation (Grundy SM et al, 1999). 
➢ Hypertension 
Hypertension can accelerate other complications of diabetes mellitus, 
particularly cardiovascular disease and nephropathy.(Tripathi B.K et al) 
1.6.ANIMALS USED FOR THE SCREENING OF ANTIDIABETIC DRUG 
1. Obese mouse 
2. Diabetic mouse 
3. Sand mouse (Psammomysobesus) 
4. Spiny mouse (Acomyscahirinus) 
5. BB rats 
6. KK mouse 
7. Yellow mouse 
8. Yellow KK mouse 
9. New Zealand obese mouse 
10. Tuco-tuco (clenomystalarum)- these are burrowing rodents from Argentina. 
11. Chinese hamster (Cricetulusgriseus) 
12. NUDE mouse 
13. Japanese wistar rat (Goto rat) etc. (www.Pharma info.net) 
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1.6.1.CHEMICALS USED TO INDUCE DIABETES MELLITUS 
A. Irreversible beta cytotoxic agents 
1. Alloxan 
2. Streptozotocin 
3. Diphenylthiocarbazine 
4. Diphenylthiocarbazine 
5. Oxine-9-hydroxyquinolone 
6. Vacor 
B. Reversible beta cytotoxic agents 
1. 6-amino nicotinamide 
2. l-aspartase 
3. Azide 
4. Cyanide 
5. Cyproheptadine 
6. Phenytoin (www.Pharmainfo.net). 
Commonly used diabetes inducing agents are, 
1. Alloxan monohydrate 
2. Streptozotocin (STZ) 
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Alloxan Monohydrate 
 The name alloxan is derived from Allantoin, a product of uric acid excreted 
bt the fetus into the allantois and oxaluric acid derived from oxalic acid and urea, 
found in urine. 
Biological effects 
 Alloxan is a toxic glucose analogue, which selectively destroys insulin-
producing cells in the pancreas (β cells) when administered to rodents and many 
other animal species. This causes an insulin-dependent diabetes mellitus (Alloxan 
Diabetes) in these animals, with characteristics similar to type I diabetes in humans. 
Mechanism of action 
Alloxan is selectively toxic to insulin-producing pancreatic beta cells 
because it preferentially accumulates in beta cells through uptakes via the GLUT2 
glucose transporter. Alloxan, in the presence of intracellular thiols, generates 
reactive oxygen species (ROS) in a cyclic reaction with its reduction product, 
dialuric acid. 
The beta cell toxic action of alloxan is initiated by free radicals formed in 
this redox reaction. One study suggests that alloxan does not cause diabetes in 
humans.  Other show some correlation between alloxan plasma level and diabetes 
Type I in children. (www.wikipedia.com) 
Strepetozotocin 
Streptozotocin or Streptozocin or Izostazin or Zanosar (STZ) is a synthetic 
antineoplastic agent that is classifically an anti-tumor antibiotic and chemically is 
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related to other nitrosureas used in cancer chemotherapy. Streptozotocin sterile 
powders are provided and prepared a chemotherapy agent. 
Each vial of sterilized Streptozotocin powder contains 1 gr. of Streptozotocin 
active ingredient with the chemical name, 2-Deoxy-2-[[(methylnitrosoamino) 
carbonyl] amino]-D-glucopyranose and 200 mg. citric acid. Streptozotocin was 
supplied by Pharmacia Company. Streptozotocin is available for intravenous use as a 
dry-frozen, pale yellow, sterilized product. Pure Streptozotocin has alkaline pH. When 
it is dissolved inside the vial in distilled water as instructed, the pH in the solution 
inside the vial will be 3.5-4.5 because of the presence of citric acid. This material is 
prepared in 1-gr vials and kept in cold store and refrigerator temperature (2-8 °C) 
away from light. (A. Akbarzadehet al, 2007) 
Glibenclamide 
 Glibenclamide is a popular antidiabetic drug, belonging to class 
ofsulfonylureas.The drug is widely used for treating type II 
diabetes.(www.neisslabs.com) 
Mechanism of action 
 The drug works by inhibiting ATP-sensitive potassium channels in 
pancreatic β cells. This inhibition causes cell membrane depolarization, opening of 
voltage dependent calcium channels, thus triggering an increase in intracellular 
calcium into the beta cell which stimulates insulin release.(www.neisslabs.com) 
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Dosage 
Dosage should be adapted to each individual patient and is determined by 
results of medical examinations. In general the initial dose is 2, 5 mg daily (half a 
glibenclamide tablet). The daily dose can then be raised gradually in steps of half 
tablets, but only after repeating medical examination. Raising the dose beyond three 
tablets daily dose not produce any increased response.When changing over from 
another oral antidiabetic preparation, with a similar mode of action, the dosage of 
Glibenclamide is determined by the amount of the previously administered dose and 
the medical examination. (www.neisslabs.com) 
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CHAPTER 2 
LITERATURE REVIEW 
Literature review is the first and most important step for the proper selection 
of plants and it also forms basis for the planning of any scientific work that has to be 
performed. Due to this reason, the review of literature regarding Pouteria 
campechianahas been done under various divisions like Pharmacognostical, 
Phytochemical, Pharmacological, Ethno medical and also miscellaneous reviews 
www.indianmedicine.eidoc. ub.rug.nl/). 
➢ Neire.M.De Gouveia et al.,Pouteria ramiflora extract inhibits 
salivaryamylolytic activity and decrease glycemic level in mice in Annals of 
the Brazilian Academy of Sciences. February 27,2013.ISSN 0001-3765. 
➢ Moustafa H Baky et al.,reportedA Review on phenolic compounds from family 
sapotaceae in Journal of pharmacognosy and phytochemistry 2016; 5(2): 280-
287.E-ISSN 2278-4136, P-ISSN 2349-8234. 
➢ Jun Ma et al., reported Analysis of Polyphenolic from the Fruits of Three 
PouteriaSpecies by selected on Monitoring Liquid Chromatography – Mass 
Spectroscopy in Journal of Agriculture and Food Chemistry 2004, 52, 5873-5878. 
➢ Adiyaman P et al.,reported Identification and qualification of polyphenolic 
compoundsin underutilized fruits (star fruit& Egg fruit) using HPLC in 
Indian journal of traditional knowledge, Vol 15(3) July 2016 pp.487-493. 
➢ Christine L.C.et al.,reportedIsolation and evaluation of  antimitotic activity of 
phenoliccompounds from pouteria campechiana.in Philipine journal of 
science137(1) ;1-10.June 2008 ISSN 0031-7683. 
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➢ Aly M Elsayed et al., reported Chemical composition and biological activities 
of Pouteria campechiana in Journal of medicinal plant research Vol.10(16) 
pp.209-215.April 25 2016.ISSN  1996-0875. 
➢ Raffi R. Isah et al., reported Potential cholesterol lowering activity of selected 
plant in Science Diliman 28:2, 83-91, July-December 2016. ISSN 0115-7809. 
➢ H.Mehraj et al ., reported Plant physiology and fruit secondary metabolites of 
Canistel (Pouteria campechiana) in World applied science journal 33(12) :1908-
1914,2015. ISSN 1818-4952. 
➢ Maduka S.de Lanerolle reported The carotenoids of Pouteria campechianain 
Journal of the National science foundation Srilanka 2008.36(1):95-98. 
➢ Sufia Syed et al., reported A Comprehensive Review on Herbal  
Hepatoprotective in anInternational Journal of Pharmaceutical 
Research(Pharmacoerena) Vol.1 Issue 2,December – 2015.ISSN 2455 – 2402. 
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CHAPTER 3 
AIM AND PLAN OF WORK 
3.1 AIM OF PRESENT STUDY 
In recent year there has been a tremendous increase in demand for herbal 
drugs due to its safety, efficacy and better therapeutic results and also due to its 
economic pricing as compared to synthetic or allopathic drugs, which have several 
therapeutic complications. 
The selection of this plant, Pouteria campechiana was made on the basis of its 
✓ High therapeutic value  
✓ Easy availability 
✓ Degree of research work which is not done  
 Very less pharmacological studies have been carried out on the leaves of  
Hence, I have decided to choose the Pouteria campechiana  project on Which  
detailed studies on Preliminary Phytochemical and Pharmacological activities of Oral 
glucose tolerance, and In-vivo Anti- diabetic studies is done. 
3.2 THE PLAN OF WORK 
The plan of work for the study of Pouteria campechianacarried out as follow. 
 Collection and authentication of raw material 
1. Preliminary phytochemical studies 
a. Preparation of extract 
b. Qualitative phytochemical studies 
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2. Pharmacological studies 
a. Acute oral toxicity study 
b. Oral glucose tolerance test 
c. Screening of Anti- diabetic activity 
➢ In-vivo study of anti-diabetic activity (Alloxan induced diabetic in high 
fat diet Rats) 
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CHAPTER 4 
PLANT PROFILE 
Plant Classification : 
Kingdom : Plantae 
Order   : Ericales 
Family : Sapotaceae 
Genus : Pouteria 
Species : Campechiana 
Common names : Egg Fruit, Canistel, Lavulu, Kunth, Baehni. 
Tree of Pouteria campechiana 
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Leaves and fruits of Pouteria campechiana 
 
Description: 
The Pouteria campechiana is an erect tree and generally not more than 8m 
tall, reach height 27-30 m and  the trunk may attain diameter of  1 m. Slender in habit 
or with a spreading crown, it has brown, furrowed bark and abundant white, gummy 
latex. Young branches are velvety brown.   
The evergreen leaves, alternate but mostly grouped at the branch tips, are 
relatively thin, glossy,short to long-stemed, oblanceolate, lanceolate-oblong, or 
obovate, bluntly pointed at the apex, more sharply tapered at the base; 11.25-28 cm 
long, 4-7.5 cm wide. 
Fragrant, bisexual flowers, solitary or in small clusters, are borne in the leaf 
axils or at leafless nodes on slender pedicles. They are 5 or 6 lobed, cream coloured, 
silky-hairy, about 8-11 mm long. 
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The fruit, extremely variable in form and size, may be nearly round, with or 
without a pointed apex or curved beak, or may be somewhat oval, ovoid, or spindle-
shaped. Length varies from 7.5-12.5 cm and width from 5-7.5 cm. On ripening, the 
skin turns lemon yellow, golden- yellow or pale orange-yellow, is very smooth and 
glossy.(Negreros-Castilloetal.,) 
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CHAPTER 5 
MATERIALS AND METHODS 
5.1 COLLECTION AND IDENTIFICATION 
5.1.1 Collection of specimen: 
 The species for the proposed study that is leaves of collected Pouteria 
campechiana carefully from thePonnani, Malappuram Dt, Kerala. 
5.1.2 Taxonomical identification: 
 The plant was positively identified by Dr.Prabhukumar.K.M Senior Scientist 
and Head, Plant Systematics and Genetic Resourse Division and CMPR 
Herbaria,Centre for Medicinal Plant Research, Arya Vaidya Sala, Kottakkal. The 
plant was authenticated as Pouteria campechiana (Kunth) Baehni of Sapotaceae 
family. 
5.1.3 Shade drying: 
 After collection, the leaves of Pouteria campechiana are washed thoroughly 
with water to remove the dirt particles and other foreign material adheres to leaves. 
Then after, the leaves were wiped off with cotton cloth and transferred to newspaper 
and evenly spreader on to paper. 
 The Pouteria campechiana leaves were subjected to shade drying to treat 
fungus until complete dryness of leaves. Then the dried leaves were powdered by 
mixer grinder until to get coarse powder, which was used for further detailed studies, 
extraction with solvent and phytochemical studies. 
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5.2.2 PRELIMINARY PHYTOCHEMICAL ANALYSIS 
Extraction of Pouteria campechiana leaves: 
Ethanol extract: 
 About 250gm of air dried powdered material was taken in 3000ml soxhlet 
apparatus and extracted with petroleum ether until green colour disappear. At the end 
of  day the powder was taken out and dried. After drying it was again packed and 
extracted by using ethanol (S.D. Fine Chemicals Ltd. Mumbai, India) as solvent, till 
colour disappeared. The temperature was maintained at 55ºC-65ºC.  After that extract 
was concentrated by distillation and solvent was recovered. The final solution 
wasevaporatedto dryness. The colour, consistency and yield of ethanolic extract were 
noted. 
Table: 5.1 Nature of extract of Pouteria campechiana 
S.No. Name of extract Colour Consistency Yield% W/W 
1. Ethanolic extract Dark Greenish Sticky mass 8 
 
5.3 CHEMICAL TESTS: 
A) Test for carbohydrates: 
1. Molisch’s Test: It consists of treating the compounds of -naphthol and 
concentrated sulphuric acid along the sides of the test tube.  
 Purple colour or reddish violet colour was produced at the junction between 
two liquids. (Kokate, C.K et al.,, 2000) 
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2. Fehling’s Test: Equal quantity of Fehling’s solution A and B is added. Heat 
gently, brick red precipitate is obtained. 
B) Test for Alkaloids: 
1. Dragendroff’s Test: To the extract, add 1ml of Dragendroff’s reagent Orange red 
precipitate is produced. 
2. Wagner’s test: To the extract add Wagner reagent. Reddish brown precipitate is 
produced. 
3. Mayer’s Test: To the extract add 1ml or 2ml of Mayer’s reagent. Dull white 
precipitate is produced.    
4. Hager’s Test: To the extract add 3ml of Hager’s reagent yellow Precipitate is 
produced. 
C) Test for Steroids and Sterols: 
1. Salkowski test: Dissolve the sample of test solution in chloroform and add equal 
volume of conc. sulphuric acid. Bluish red cherry red and purple color is noted in 
chloroform layer, whereas acid assumes marked green fluorescence. 
D) Test for Glycosides: 
1. Borntrager test: Add a few ml of dilute sulphuric acid to the test solution. 
Boil, filter and extract the filtrate with ether or chloroform. Then organic layer 
is separated to which ammonia is added, pink, red or violet colour is produced 
in organic layer. 
2. Killer Killani test: Sample is dissolved in acetic acid containing trace of 
ferric chloride and transferred to the surface of concentrated sulfuric acid. At 
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the junction of liquid reddish brown color is produced which gradually 
becomes blue. 
E) Test for Saponins: 
 Foam test: About 1ml of alcoholic sample is diluted separately with distilled 
water to 20ml, and shaken in graduated cylinder for 15 minutes.1 cm layer of foam 
indicates the presence of saponins. 
F) Test for Flavonoids 
 Ferric chloride test – Test solution when treated with few drops of Ferric 
chloride solution, blackish red color indicating the presence of flavonoids. 
 Alkaline reagent Test – Test solution when treated with sodium hydroxide 
solution, shows increase in the intensity of yellow color which would become 
colorless on addition of few drops of dilute Hydrochloric acid, indicates the presence 
of flavonoids. 
 Lead acetate solution Test – Test solution when treated with few drops of 
lead acetate (10%) solution, no yellow precipitate is formed presence of flavonoids. 
G) Test for Tri-Terpenoids: 
 In the test tube, 2 or 3 granules of tin was added, and dissolved in a 2ml of 
thionyl chloride solution and test solution is added. Pink colour is produced which 
indicates the presence of triterpenoids. 
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H) Tests for Tannins and Phenolic Compounds: 
 To 2-3 ml of extract, add few drops of following reagents:  
a)  5% FeCl3 solution: deep blue-black color. 
c)  Gelatin solution: white precipitate not formed 
K) Test for Proteins and Amino acids 
a) Biuret test: 
 Add 1 ml of 40% sodium hydroxide and 2 drops of 1% copper sulphate to the 
extract, a violet colour indicates the presence of proteins. 
b) Ninhydrin test: 
 Add 2 drops of freshly prepared 0.2% Ninhydrin reagent to the extract and 
heat. A blue colour develops indicating the presence of proteins, peptides or amino 
acids. 
c) Xanthoprotein test: 
To the extract, add 20% of sodium hydroxide or ammonia. Orange colour 
indicates presence of aromatic amino acid. 
5.5 PHARMACOLOGICAL EVALUATION: 
5.4 TOXICOLOGICAL EVALUATION 
Determination of LD50value of ethanolic extract of Pouteria campechiana 
Acute Oral Toxicity Study: 
The procedure was followed by using OECD guidelines 423 (Acute toxic class 
method). The acute toxic class method is a step wise procedure with 3 animals 
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ofsingle sex per step. Depending on the mortality and / or moribund status of the 
animals, on average 2-4 steps may be necessary to allow judgment on the acute 
toxicity of the test animals while allowing for acceptable data based scientific 
conclusion.  
The method uses defined doses (5, 50, 300, 2000mg/kg body weight) and the 
results allow a substance to be ranked and classified according to the Globally 
Harmonized System (GHS) for the classification of chemical which cause acute 
toxicity. 
Animals: 
 Female albino mice weighing 20-25g were used in the present study. All rats 
were kept at room temperature of 22-25ºC in the animal house. All the animals were 
followed the internationally accepted ethical guidelines for the care of laboratory 
animals. Prior to the experiments, rats were fed with standard food for one week in 
order to adapt to the laboratory conditions.  The experimental protocol has been 
approved by institutional animal ethics, committee, JKKMMRF College of 
Pharmacy,Proposal number – JKKMMRFCP/IAEC/2017/001 B.Komarapalayam, 
Namakkal.  
Procedure: 
 Twelve animals Albino mice, (25-30gm) were selected for studies.  
 The starting dose of ethanolic extracts of Pouteria campechiana  300mg/kg, 
b.w, p.o, was administered. 
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 Most of the crude extracts possess LD50, value more than 2000mg/kg of the 
body weight of the animal used. Dose volume was administered 0.1ml/100gm body 
weight to the animal by oral route. 
 After giving the dose toxic signs were observed within 3-4 hours. Body weight 
of the animals before and after administration, onset of toxicity and signs of toxicity 
like changes in the skin and fur, eyes and mucous membrane and also respiratory, 
circulatory, autonomic and central nervous systems and somatomotor activity and 
behavior pattern, sign of tremors, convulsion, salivation, diarrhea, lethargy and sleep 
and coma was also to be noted, if any, was observed. The animal toxic or death was 
observed upto 14 days. 
Observation 
 Acute toxicity studies and evaluation of dates are studied as per the guideline 
of OECD (423). 
 No toxicity or death was observed for these given dose levels, in selected and 
treated animals. So the LD50 of the ethanolic extract of leaves of Pouteria 
campechianawasgreater than 2000mg/kg (LD50>2000mg/kg). 
 Hence the biological dose was fixed at three levels, 200 and 400mg/kg body 
weight for the extract. 
5.5.1 ORAL GLUCOSE TOLERANCE TEST (OGTT): 
 The overnight fasted (18hr) normal rats were taken and divided into 
fourgroups consists of six animals. They were provided with drinking water only. 
Normal saline solution was administered to group I animals. Group II animals were 
received Glibenclamide (3mg/kg,b.w) as a standard. Pouteria campechiana ethanol 
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extract (200 and 400 mg/kg) was administered by oral route to group III and IV 
Glucose (2mg/kg) load was fed 30 minutes after the administration of extracts. Blood 
was withdrawn from tail vein under mild ether anesthesia initial, 30,60 and 90 
minutes after glucose administration  and glucose level were estimated using glucose 
strips and a glucometer(Standard diagnostics Ltd). Blood glucose levels were noted 
and reported. 
5.5.2 EVALUATION OF ANTI-DIABETIC ACTIVITY: 
Animals: 
 Wistar albino rats (150-200g) were selected for either sex, for studies and they 
were kept in a standard polypropylene cage at room temperature of 27±2oC, relative 
humidity 60-70% and well ventilated. They were fed a standard rat pellet and water 
adlibtium. Animals were deprived of food initially for 16 hrs but had free access to 
water.  The experimental protocol has been approved by institutional animal ethics, 
committee, JKKMMRF College of Pharmacy, Proposal number – 
JKKMMRFCP/IAEC/2017/001 B.Komarapalayam, Namakkal. 
Chemicals: 
 Alloxan monohydrate (LOBA Chemie, Mumbai, India) was purchased, 
preserved at 25ºC and used for this study.   
 Glibenclamide is an oral antidiabetic preparation with an efficient 
hypoglycemic action. Daonil (Glibenclamide) (S.K.Prasad et.al, 2009) manufactured 
by Aventis Pharma Ltd. Goa, India, was collected from market and preserved at room 
temperature. 
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Induction of Experimental Diabetes: 
Hyperglycemia / Diabetes was induced by single intraperitonial injection of 
freshly prepared aqueous solution of alloxan monohydrate 150 mg/kg, to overnight 
fasted rats. After 48 hrs of alloxan injection, the animals which did not developed 
hyperglycemia i.e glucose level > 200mg/dl, were injected or replaced.Immediately 
after confirmation of diabetes, rats were classified into five groups of six rats 
each.Standard drug used for treatment, Glibenclamide, 5 mg/kg, ethanolic test extract 
were prepared, 200mg/kg and 400mg/kg in 2% Carboxy Methyl Cellulose(CMC) and 
were given orally. Taking six rats in each five groups did evaluation of antidiabetic 
effect.(G.Jyothi et al., 2013) 
Experimental Design: 
Experimental rats were divided into 5 groups of six animals each all the group 
of animals were induced diabetic except control and treated for 21days as follows. 
➢ Group I: Normal control rats fed with vehicles only. (Normal saline with 
1%CMC) 
➢ Group II: Diabetic controls rats(Alloxan monohydrate 120mg/kg body weight of 
rats, once i.p injection).  
➢ Group III: Diabetic rats treated with standard drug, Glibenclamide 3mg/kg per 
oral body weight. 
➢ Group IV: Diabetic rats treated with ethanolic extract of Pouteria 
campechiana200mg/kg, per oral, dissolved in 1% carboxy methyl cellulose 
(CMC). 
➢ Group V: Diabetic rats treated with ethanolic extract of Pouteria campechiana 
400mg/kg, per oral, dissolved in 1% carboxy methyl cellulose (CMC). 
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Sample collection:  
Fasting blood glucose (FBG) of all rats was determined before the start of the 
experiment. Blood sample was collected at weekly intervals from tail vein puncture 
till the end of study. In the continuous 21 days of drug treatment, a blood glucose 
level of all animals was determined at the 0, 7, 14, 21 day by using one touch 
glucometer (SD Check) method. 
5.6 EVALUATION OF PARAMETERS: 
1. Estimation of changes in body weight of the animals: 
Body weight of all rats was measured on starting day (0 day) of the 
experiment and 21stday of the experiment. Both initial and final body weights were 
noted and reported. 
2. Estimation of blood glucose level: 
 Glucose level in plasma was estimated by glucose oxidase/ peroxidase method 
using a commercial kit from Med source Ozone Biomedicals Pvt Ltd followed by 
Trinder, p.(1969)Annals.Clin. Bio chem.6,24. 
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Reagents: 
1. Enzyme reagent 
2. Buffer solution 
3. Glucose standard (100 mg%) 
Procedure: 
 10 µl of plasma was added to 1.0 ml of working enzyme reagent, mixed well 
and incubated at 37°C for 15 min. The colour developed was read at 505 nm against 
blank containing distilled water instead of the sample. A standard was also processed 
similarly. 
 The level of glucose is expressed as mg/dl. 
5.8 STATISTICAL ANALYSIS 
 All the values of body weight and fasting blood glucose level were expressed 
as mean ± standard error of mean (S.E.M) and was analyzed for significance by 
ANOVA and groups were compared by Tukey-Kramer multiple comparison test. 
Differences between groups (p Value) were considered significant at P<0.05 level.  
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CHAPTER 6 
RESULTS AND DISCUSSION 
 Based on literature review the leaves of Pouteria campechianawere selected 
and project work was carried on Pouteria campechianat.belonging to the family 
Sapotaceae was collected and authenticated. The result of the present study show that 
the ethanol extract ofexerts anti-diabetic Pouteria campechianaeffective against 
alloxan induced diabetes. 
6.1 PHARMACOGNOSTICAL STUDIES  
6.1.1 ANALYTICAL PARAMETERS 
6.2 PRILIMINARY PHYTOCHEMICAL STUDIES 
Table No.6.3: Weight of extract of Pouteria campechiana 
Name of extract Yield(%w/w) 
Ethanol 8 
 
 The extract obtained were subjected to qualitative Phytochemical test to find 
out the active constituents. 
Table No.6.4: Qualitative Phytochemical analysis of heart wood parts extract 
TEST FOR PHYTOCONSTITUENTS RESULT 
Saponins _ 
Alkaloids + 
Glycosides + 
Tannins and phenolic compounds +, _ 
Carbohydrates + 
Proteins and aminoacids + 
Flavonoids + 
Steroids + 
 
(+) - Present (-) - Absent 
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DISCUSSION: 
 The preliminary Phytochemical studies were done in the ethanolic extract of 
Pouteria campechiana leaves result suggest that presence of Alkaloids, 
Carbohydrate, Glycosides, Proteins and aminoacids, flavonoids, Steroids,  and 
tannins. 
6.3 PHARMACOLOGICAL STUDIES 
6.3.1 ACUTE ORAL TOXICITY STUDIES 
 The acute oral toxicity of the ethanolic extract of Pouteria campechiana was 
carried out as per OECD 423-guidelines (Acute toxic class method). Acute toxicity 
studies revealed that LD50>2000mg/kg for the extract. Hence, the biological dose was 
fixed at EEPC 200mg and 400mg of body weight for the extract. 
6.3.2 EFFECT ON GLUCOSE TOLERANCE 
 In OGTT, the doses of EEPC 200 mg/kg and 400 mg/kg increased the 
tolerance for glucose suggesting increased peripheral utilization of glucose. The 
reduction in blood glucose level was dose dependent. 
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Table No.: 6.6 Effect of ethanolic extract of Pouteria campechiana and 
Glibenclamide on glucose tolerance of diabetic rats. 
Groups Treatment 
Change in blood glucose levels(mg/dl) 
Fasting 
After 30 
Minutes 
After 60 
minutes 
After 90 
minutes 
1. Glucose 
2mg/kg 
84.99±2.90 125.22±2.02 127.88±1.90 108.51±2.89 
2. Glibenclamide 
3mg/kg 
68.01±3.32 83.10±1.50 a 62.01±2.55 a 52.71±3.24 a 
3. EEPC 
200mg/kg 
67.05±1.49 113.08±6.99 b 113.76±3.02 96.42±2.98 a 
4. EEPC 
400mg/kg 
78.69±2.80 99.92±1.99 a 105.11±7.88 b 90.65±1.91 a 
 
 Values are given as mean ± S.E.M for groups of six animals each. Values are 
statistically significant at a=*** = p<0.001; b= ** = p<0.01; c= * =p<0.05.EEAN. 
(Analyzed by one-way analysis of variance (ANOVA) followed by Tukey-Kramer 
multiple comparison tests). Normal control group I was compared with group 2(std 
drug) and extract treated groups III , IV. 
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Figure No.6.1: Effect of ethanolic extract of Pouteria campechiana and 
Glibenclamide on glucose tolerance of diabetic rats. 
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6.3.4 EVALUATION OF PARAMETERS 
1. Changes in body weight: 
 Vehicles control animals were found to be stable in their body weight but 
significant reduction in diabetic control group during 21 days (Table. 6.7). Alloxan 
caused body weight reduction, which is slightly reversed by ethanolic extract of 
Pouteria campechiana treated (200mg/kg and 400mg/kg) groups after 21 days. 
While, significant (p<0.01,p<0.001) increase in body weight was observed in 
rats treated with ethanolic extract of Pouteria campechiana The EEPC treated 
diabetic rats (400mg/kg) were slightly increased the body weight level and showed in 
Table No: 6.7, Fig No: 6.2. 
Table No: 6.7 Body weight changes in ethanolic extract ofPouteria campechiana 
and Glibenclamide on control and experimental groups of rats 
Group Treatment 
Body weight changes (g) 
Day 0 Day 21 
I Normal control rats (vehicles only) 145±7.67 204.15±11.94 
II Diabetic control rats  162.5±8.54 b 129.18±7.67 b 
III Diabetic group + Glibenclamide 5mg/kg  150±2.44 a 208.37±02.37 a 
IV Diabetic group + EEPC (200mg/kg) 154.17±7.67 b 200±6.46 b 
V Diabetic group + EEPC (400mg/kg) 162.6±04.05 a 210.6±17.98 c 
 
Values are given as mean ± S.E.M for groups of six animals each. Values are 
statistically significant at a=*** = p<0.001; b= ** = p<0.01; c=* =p<0.05. (Analyzed 
by one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple 
comparison tests). (Diabetic control group II was compared with Normal control 
group I, group III and extract treated groups IV, V compared with Diabetic control 
group II.) 
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Figure: 6.2 Body weight changes in ethanolic extract of and Pouteria 
campechiana Glibenclamide on control and experimental groups of rats 
Values are given as mean ± S.E.M for groups of six animals each. Values are 
statistically significant at a=*** = p<0.001; b= ** = p<0.01; c=* =p<0.05. (Analyzed 
by one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple 
comparison tests). (Diabetic control group II was compared with Normal control 
group I, group III and extract treated groups IV, V compared with Diabetic control 
group II.) 
2. Changes in blood glucose: 
 A significant increase in the level of blood glucose, was observed in diabetic 
control rats when compared to control rats. Administration of EEPC and Glibencla 
mide to diabetic rats significantly decreased the elevated level of blood glucose, near to 
control level. Showed Table No: 6.8, Figure No: 6.4. 
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Table No. 6.8. Effect of Pouteria campechiana ethanolic extract of and Glibenclamide on blood glucose level 
Group Treatment 
Blood glucose level (mg/dl) 
Day 0 Day 7 Day 14 Day 21 
I Normal control rats (vehicles only) 70.65±1.42 80±2.34 78.83±2.36 72.33±1.82 
II Diabetic control rats 380.6±1.57 a 336.84±2.18 a 354.84±2.81 a 369.32±1.09 a 
III 
Diabetic group + Glibenclamide 
3mg/kg 
313.6±2.09 a 281.34±1.56 a 233.65±1.42 a 147.67±1.05 a 
VI Diabetic group + EEPC (200mg/kg) 334.66±8.90 c 285±03.26 a 174.82±2.91 a 161±2.08 a 
V Diabetic group + EEPC (400mg/kg) 
321.84±12.16 
c 
286±5.08 b 157.82±1.30 a 160.5±2.74 a 
 
Values are expressed as Mean ±SE, n = 6 by Dunnett’s t test; *P <0.01 Vs Control **P > 0.001 Vs Control. 
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Figure No: 6.4 Effect of ethanolic extract of Pouteria campechiana and 
Glibenclamide on blood glucose level. 
 
Values are given as mean ± S.E.M for groups of six animals each. Values are 
statistically significant at a=*** = p<0.001; b= ** = p<0.01; c=* =p<0.05. (Analyzed 
by one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple 
comparison tests). (Diabetic control group II was compared with Normal control 
group I, group III and extract treated groups IV, V compared with Diabetic control 
group II.) 
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CHAPTER 7 
SUMMARY AND CONCLUSION 
 The leaves of Pouteria campechiana belonging to the family sapotaceae has 
been examined to gain an insight of its phytochemical and pharmacological behavior. 
The preliminary phytochemical investigation of powdered Pouteria 
campechiana showed the presence of Carbohydrates, Alkaloids, Glycosides, Steroid, 
Terpenoids, Flavonoids, Proteins and Amino acids. 
The pharmacological and acute toxicity studies of ethanolic extract was 
performed by following, OECD-423 guidelines (Acute toxic class method). No 
mortality or acute toxicity was observed upto 2000mg/kg of body weight. The 
Biological dose of extract Pouteria campechiana dose was selected 200mg/kg and 
400mg/kg in this dose possessed significant antidiabetic activity. 
Alloxan causes a massive destruction of β-cells of the isletsof langher-hans, 
resulting in reduced synthesis and release of insulin. The function of the insulin 
suppressed, which leads to high level of hyperglycemic and eventually to death,but 
the different extracts of pouteria campechiana showed antidiabetic effect in alloxan 
induced diabetic rats and reduced the mortality rate significantly. 
Overall, it can be concluded that ethanolic extract of Pouteria campechiana 
can be used as a natural source of anti-diabetic activity. Further pharmacological and 
biochemical studies are needed to isolate and characterize active compound 
responsible for the anti-diabetic activity. 
Chapter 7 Summary and Conclusion 
Department of Pharmacology           75 JKKMMRFCollege of Pharmacy 
CHAPTER 8 
BIBILIOGRAPHY 
➢ Adiyaman P et al.,reported Identification and qualification of polyphenolic 
compoundsin underutilized fruits (star fruit& Egg fruit) using HPLC in 
Indian journal of traditional knowledge, Vol 15(3) July 2016 pp.487-493. 
➢ Aiello LP, Gardner TW, King GL et al., Diabetic retinopathy. Diabetes Care, 
1998; 21: 143–56. 
➢ Akbarzadeh, D. Norouzian, M.R. Mehrabi, Sh. Jamshidi, A. Farhangi, A. Allah 
Verdi, S.M.A. Mofidian1 and B. Lame Rad:Induction of diabetes by 
streptozotocin in rats , Indian Journal of Clinical Biochemistry, 2007 /22 (2) 
60-64. 
➢ Aly M Elsayed et al., reported Chemical composition and biological 
activities of Pouteria campechiana in Journal of medicinal plant research 
Vol.10(16) pp.209-215.April 25 2016.ISSN  1996-0875. 
➢ American Diabetes Association (ADA): Report of the expert committee on the 
diagnosis and classification of diabetes mellitus. Diabetes Care,2001; 
24(Suppl.1): S5–S20. 
➢ American Diabetes Association (ADA): Report of the expert committee on the 
diagnosis and classification of diabetes mellitus. Diabetes Care,2001; 
24(Suppl.1): S5–S20. 
➢ Atkinson MA, Eisenbarth GS: Type I diabetes: new prospective on disease 
pathogenesis and treatment,Lancet, 2001; 358(9277): 221–29. 
Chapter 7 Summary and Conclusion 
Department of Pharmacology           76 JKKMMRFCollege of Pharmacy 
➢ Bergman RN, Lilly lecture: Toward physiological understanding of glucose 
tolerance. Minimal model approach. Diabetes, 1989; 38: 1512–27. 
➢  Bliss M. The discovery of insulin. Chicago: University of Chicago Press, 
1982. 
➢ Bodhisattwa Maiti, Nagori B.O., Rambir Singh 1, Pragati Kumar and Nishant 
Upadhayay(2011). Recent trends in herbal drugs: a review . International 
journal of drug research and technology , 1 (1) 
➢ Bolli G B, Owens DR, Insulin glargine . Lancet,2000 356: 443-445. 
➢ Chen YD, Reaven GM: Insulin resistance and atherosclerosis. Diabetes Rev, 
1997; 5: 331–43. 
➢ Christine L.C.et al.,reportedIsolation and evaluation of  antimitotic activity 
of phenoliccompounds from pouteria campechiana.in Philipine journal of 
science137(1) ;1-10.June 2008 ISSN 0031-7683. 
➢ De Meyts, P. The structural basis of insulin and insulin-like growth factor-I 
receptor binding and negative co-operativity, and its relevance to mitogenic 
versus metabolic signalling. Diabetologia, 1994, 37:S135-148. 
➢ Debjit Bhowmik, M.Umadevi, K.P. Sampath Kumar, S. Duraive(2013). 
Traditionally used anticancer drugs in India. Journal of medicinal plants 
studies, 1 (3):56-57.  
➢ DeFronzo RA: Pathogenesis of type 2 diabetes: metabolic and 
molecularimplication for identifying diabetes genes. Diabetes Rev, 1997; 
5:177–267. 
Chapter 7 Summary and Conclusion 
Department of Pharmacology           77 JKKMMRFCollege of Pharmacy 
➢ Essawi.T, Srour.M, (2000). Screening of some Palestinian medicinal for 
antibacterial activity. Journal of Ethnopharmacology, 70:343-349. 
➢ Fabricant. D.S, Farnsworth.N.R,(2001). The value of plants used in traditional 
medicine for drug discovery. Environment and health perspectives, 
109(suppl.1):69-75. 
➢ Fajans SS, Bell GI, Polonsky KS: Molecular mechanisms and clinical 
pathophysiology of maternity-onset diabetes of the young. N Engl J Med, 2001; 
345: 971–80. 
➢ Farnsworth.N.R, Morris.R.W (1976). Higher plant: the sleeping giant of drug 
development. American journal of pharmaceutical education. 148:46-52. 
➢ Galloway JA, Chance RE. Improving insulin therapy: in 1994. 
➢ Gilani.A.H, Rahman.A.V (2005), Trends in Ethnopharmacology. Journal of 
Ethnopharmacology; 100:43-49. 
➢ Goodman and Gilman’s the pharmacology basis of therapeutics : 11th edition , 
chapter: 60 in 2006. 
➢ Grundy SM, Benjamin IJ, Burke GL et al., Diabetes and cardiovascular 
disease: A statement for healthcare professionals from the AmericanHeart 
Association. Circulation, 1999; 100: 1134–46. 
➢ Gupta, M.P.Solis, P.N.Calderon, A.J.Guinneau inclair, F.Correa, M.Gladames, 
C.Gurra, C.Espinosa, A.Alvenda, G.L.Rovles G&Olampo(2005). Medical 
ethanobotany of the tribes of Bocas del Toro, Panama.Journal of 
ethnopharmacology 96:389-401. 
Chapter 7 Summary and Conclusion 
Department of Pharmacology           78 JKKMMRFCollege of Pharmacy 
➢ H.Mehraj et al ., reported Plant physiology and fruit secondary metabolites 
of Canistel (Pouteria campechiana) in World applied science journal 33(12) 
:1908-1914,2015. ISSN 1818-4952. 
➢ Hazeena Begum V and Velvan.S. (2011).Lipids regulating activity of 
Asparagus racemosus root in young and aged rats. Indian Journal of 
Gernotology, 25(3):273-285. 
➢ http://www.ucsfhealth.org/conditions/diabetes_mellitus/signs and symptoms. 
html. 
➢ http://www.ucsfhealth.org/conditions/diabetes_mellitus/signs and symptoms. 
html. 
➢ http://www.webmd.com/diabetes/types-of-diabetes-mellitus 
➢ http://www.webmd.com/diabetes/types-of-diabetes-mellitus. 
➢ Ignacimthu.S. and Ayyanar M(2009). Herbal medicines for wound healing 
among tribal people in southern India: Ethno botanical and scientific evidences. 
International Journal of Applied Research in Natural Products, 2(3): 29-42. 
➢ Jun Ma et al., reported Analysis of Polyphenolic from the Fruits of Three 
Pouteria Species by selected on Monitoring Liquid Chromatography – 
Mass Spectroscopy in Journal of Agriculture and Food Chemistry 2004, 52, 
5873-5878. 
➢ Jyothi. G, Narendra chary.T, N.Lal Mahammed, Ch Venkateswara Reddy and 
G. Nagarjuna Reddy ,Antidiabetic activity of the Ethanolic Extract of root of  
Mang Iifera indica on Alloxan induced rats in International journal of 
Chapter 7 Summary and Conclusion 
Department of Pharmacology           79 JKKMMRFCollege of Pharmacy 
pharmaceutical and chemical sciences. ISSN 2277-5005, Vol.2(2) Apr-Jun 
2013. 
➢ Kahn, C.R., and Roth, J. Berson, Yalow, and the JCI: The agony and the 
ecstasy. J. Clin.Invest., 2004, 114:1051-1054. 
➢ Kokate C.K, Purohit A.P, Gokhale S.B (2012), text book of pharmacognosy, 
47th edition, vol 1 & 2. 
➢ Kokate, C.K, Evaluation of crude drug, Practical Pharmacognosy, 4thedn, 
2000, p.no:122-135. 
➢ Kokate, C.K, Practical Pharmacognosy, 1st edition, 2002, p.no: 107-114, 123-
125, 130, 405-406, 426-489. 
➢ Lai, P.K & J. Roy (2004).Antimicrobial and chemo preventive properties of 
herbs and spices. Curr.Med.Chem, 11(11):1451-1460. 
➢ Lernmark A, Ott J: Sometimes it’s hot, sometimes it’s not. Nat Genet,1998; 19: 
213–14. 
➢ MacCracken J. Puzzles and promises in diabetes management. Postgrad Med 
1997;101:138-40,143-5,149-50. Nakae, J., Kido, Y., and Accili, D. Distinct and 
overlapping functions of insulin and IGF-I receptors. Endocr. Rev., 
2001, 22:818-835. 
➢ Maduka S.de Lanerolle reported The carotenoids of Pouteria campechiana in 
Journal of the National science foundation Srilanka 2008.36(1):95-98. 
Chapter 7 Summary and Conclusion 
Department of Pharmacology           80 JKKMMRFCollege of Pharmacy 
➢ Maheswari. J.K, Singh. K.K & Saha.S (1986). Ethnobotany ofribals of 
Mirzapur district, Uttarpradesh. Economic botany, Information service. NBRI, 
Lucknow,1-38. 
➢ Moustafa H Baky et al., reported A Review on phenolic compounds from 
family sapotaceae in Journal of pharmacognosy and phytochemistry 2016; 
5(2): 280-287.E-ISSN 2278-4136, P-ISSN 2349-8234. 
➢ Nakae, J., Kido, Y., and Accili, D. Distinct and overlapping functions of insulin 
and IGF-I receptors. Endocr. Rev., 2001, 22:818-835. 
➢ Negreros-Castilo P and Hall R.B 1994, Journal of environmental management 
41(3): 237-243. 
➢ Neire.M.De Gouveia et al., Pouteria ramiflora extract inhibits 
salivaryamylolytic activity and decrease glycemic level in mice in Annals of 
the Brazilian Academy of Sciences. February 27,2013.ISSN 0001-3765. 
➢ Prasad. S.K., AlkaKushreshtha and Taj N. Qureshi,Antidiabetic activity of 
some herbal plants in streptozotocin induced diabetes in rats, Pakistan journal 
of nutrition,2009, p.no: 551-557. 
➢ Raffi R. Isah et al., reported Potential cholesterol lowering activity of 
selected plant in Science Diliman 28:2, 83-91, July-December 2016. ISSN 
0115-7809. 
➢ Ritz E, Orth SR: Nephropathy in patients with type 2 diabetes. N Engl J Med, 
1999; 341: 1127–33. 
Chapter 7 Summary and Conclusion 
Department of Pharmacology           81 JKKMMRFCollege of Pharmacy 
➢ Salie F, Eagles P F K, Lens HMJ(1996). Preliminary antimicrobial screening of 
four south Africans asteraceae species. Journal of ethnopharmacology, 52(1): 
27-33. 
➢ Sufia Syed et al., reported A Comprehensive Review on Herbal  
Hepatoprotective in an International Journal of Pharmaceutical Research 
(Pharmacoerena) Vol.1 Issue 2,December – 2015.ISSN 2455 – 2402. 
➢ Taylor SI, Arioglu E: Genetically defined forms of diabetes in children. J Clin 
Endocrinol Metabl, 1999; 84: 4390–96. 
➢ Tripathi.K.D, Essential of Medical Pharmacology sixth edition in 2008 
➢ Wink.M, Alfermann A.W, Franke.R, Wetteraur.B, Disstl M, Windhivel J, 
Krohno.O, Fuss.E, Garden.H, Mohagheghzadeh.A, (2005). Sustainable 
biproduction of phytochemicals by plant in-vitro cultures:Anticancer agents. 
Plants Gene Res.3:90-100. 
➢ World Health Organization (WHO): Definition, Diagnosis and classification of 
diabetes mellitus and its complications. Part 1: Diagnosis and classifications of 
diabetes mellitus. Department of Non-communicable Disease Surveillance, 
Geneva, 1999. 
➢ www.indianmedicine.eidoc.ub.rug.nl 
➢ www.neisslabs.com 
➢ www.Pharma info.net. 
➢ www.Pharma info.net. 
